BioNet Europe
1 products tracked · names used in filings: BioNet Europe
Upcoming milestones
No upcoming milestones listed.
Recent milestones
Fri 09 Jan 2026🇪🇺 EU approval (EC decision)
VacPertagen (pertussis vaccine (recombinant, acellular, component, adsorbed)) approved in the EU
Marketing authorisation to BioNet Europe · source
Thu 13 Nov 2025🇪🇺 CHMP positive opinion
VacPertagen (pertussis vaccine (recombinant, acellular, component, adsorbed)): CHMP positive opinion
Products
| Product | Status | Approved | |
|---|---|---|---|
| 🇪🇺 | VacPertagen pertussis vaccine (recombinant, acellular, component, adsorbed) | Authorised | 2026-01-09 |
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.